Zita-Met 1000mg/20mg Tablet ER is a combination oral antidiabetic medication containing Metformin hydrochloride 1000mg and Teneligliptin 20mg, formulated as an extended-release tablet. Metformin, a biguanide class agent, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which promote glucose-dependent insulin secretion and suppress glucagon release, contributing to improved glycemic control. This fixed-dose combination is indicated for the management of type 2 diabetes mellitus in patients inadequately controlled by diet, exercise, and monotherapy. The extended-release formulation ensures a sustained plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Zita-Met should be used as part of a comprehensive diabetes management plan including diet and exercise. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. This combination offers a synergistic approach to glycemic control by targeting multiple pathophysiological defects in type 2 diabetes.